TABLE 2.
Baseline information in phase II
| Categories | Multicenters | |||||
|---|---|---|---|---|---|---|
| PPC (N = 1,595) | PPC1 (N = 778) | PPC2 (N = 817) | PPC3 (N = 435) | PPC4 (N = 323) | PPC5 (N = 478) | |
| Gender (male), n (%) | 1,123 (70.41%) | 605 (77.76%) | 518 (63.4%) | 370 (85.06%) | 260 (80.5%) | 308 (64.44%) |
| Age, b median (IQR), years | 60 (51–68) | 58 (50–66) | 62 (52–72) | 55 (47–63) | 56 (49–66) | 62 (53–73) |
| First clinical diagnosis, c n (%) | — | — | — | — | — | — |
| Postoperation of tumor/liver transplantation | 778 (48.78%) | 778 (100.00%) | — | 344 (79.08%) | 236 (73.07%) | 16 (3.35%) |
| Viral hepatitis | 91 (5.71%) | — | 91 (11.14%) | 91 (20.92%) | 26 (8.05%) | 1 (0.21%) |
| Liver cirrhosis | 61 (3.82%) | — | 61 (7.47%) | — | 61 (18.89%) | 2 (0.42%) |
| Space-occupying lesions/postoperative | 114 (7.15%) | — | 114 (13.95%) | — | — | 3 (0.63%) |
| Abnormal liver function | 456 (28.59%) | — | 456 (55.81%) | — | — | 456 (95.40%) |
| Drug-induced liver injury | 7 (0.44%) | — | 7 (0.86%) | — | — | - |
| Autoimmune liver disease | — | — | — | — | — | - |
| Alcoholic liver disease | 1 (0.06%) | — | 1 (0.12%) | — | — | — |
| Nonalcoholic fatty liver disease | 46 (2.88%) | — | 46 (5.63%) | — | — | — |
| Hepatic encephalopathy | 1 (0.06%) | — | 1 (0.12%) | — | — | — |
| Hepatic vascular diseases | 4 (0.25%) | — | 4 (0.49%) | — | — | — |
| Nonneoplastic diseases of the biliary tract | 25 (1.57%) | — | 25 (3.06%) | — | — | — |
| Others | 11 (0.69%) | — | 11 (1.35%) | — | — | — |
| Basic chronic disease, n (%) | — | — | — | — | — | |
| Hypertension | 364 (22.82) | 101 (12.98) | 263 (32.19) | 66 (15.17) | 45 (13.93) | 178 (37.24) |
| Diabetes | 205 (12.85) | 53 (6.81) | 152 (18.60) | 33 (7.59) | 32 (9.91) | 93 (19.46) |
| Hyperlipidemia | 15 (0.94) | 1 (0.13) | 14 (1.71) | 1 (0.23) | 0 (0.00) | 6 (1.26) |
| Surgery situation, n (%) | — | — | — | — | — | — |
| Nonsurgery | 918 (57.55) | 342 (43.96) | 576 (70.5) | 202 (46.44) | 148 (45.82) | 364 (76.15) |
| Surgery may affect liver function (ALT) | 429 (26.9) | 331 (42.54) | 98 (12.0) | 196 (45.06) | 132 (40.87) | 39 (8.16) |
| No significant/unknown effect of surgery on liver | 248 (15.55) | 105 (13.5) | 143 (17.5) | 37 (8.51) | 43 (13.31) | 75 (15.69) |
| Function(ALT) | ||||||
| Total days of using PPC, days, median (IQR) | 8 (5–12) | 8 (5–12) | 8 (5–12) | 8 (5–12) | 9 (6–13) | 8 (6–12) |
| Hospitalization days, days, median (IQR) | 11 (8–17) | 10 (8–15) | 13 (8–20) | 11 (8–14) | 11 (8–15) | 13 (9–20) |
| Total treatment cost, CNY, median (IQR) | 27,925 (17,409–54,349) | 23,525 (16,707–42,766) | 35,012 (18,152–63,819) | 23,768 (16,417–42,885) | 23,047 (16,124–39,189) | 45,546 (22,266–72,113) |
Notes: PPC1 indicates using PPC injection alone and liver disease spectrum is “postoperation of tumor/liver transplantation”; PPC2 indicates using PPC injection alone and liver disease spectrum is “postoperation of nontumor/liver transplantation”; PPC3 indicates using PPC injection alone and liver disease spectrum is “viral hepatitis”; PPC4 indicates using PPC injection alone and liver disease spectrum is “liver cirrhosis”; PPC5 indicates using PPC injection alone and liver disease spectrum is “abnormal liver function”.
Hospitalization records were recorded according to the time of admission, and the record of multiple hospitalizations of one patient is not reprocessed.
Age (years) = (admission date in the hospitalization record—date of birth in the patient’s information)/365.25.
The first clinical diagnosis was based on discharge diagnosis.
Abbreviations: Min, minimum; Max, maximum; IQR, interquartile range; PPC, polyene phosphatidyl choline; CNY, China yuan; ALT, alanine transaminase.